APO Research
Talk to an analyst

APO RESEARCH · REPORT

Oral and Injectable Medications for Type 2 Diabetes

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Oral and Injectable Medications for Type 2 Diabetes Market Analysis and Forecast 2026-2032

23 December 2025200 pages

Choose your research edition.

Industry ResearchOral and Injectable Medications for Type 2 Diabetes Industry Research Report 2026133 pages · $2,950 USDIndustry Growth & TrendsGlobal Oral and Injectable Medications for Type 2 Diabetes Industry Growth and Trends Forecast to 2032115 pages · $3,450 USDMarket StructureGlobal Oral and Injectable Medications for Type 2 Diabetes Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Oral and Injectable Medications for Type 2 Diabetes Market Outlook and Growth Opportunities 2026202 pages · $4,250 USDMarket Analysis & ForecastGlobal Oral and Injectable Medications for Type 2 Diabetes Market Analysis and Forecast 2026-2032200 pages · $4,950 USD

Market perspective

The global Oral and Injectable Medications for Type 2 Diabetes market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Oral and Injectable Medications for Type 2 Diabetes is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Oral and Injectable Medications for Type 2 Diabetes is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Oral and Injectable Medications for Type 2 Diabetes is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Oral and Injectable Medications for Type 2 Diabetes is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Oral and Injectable Medications for Type 2 Diabetes include United Laboratories, Yiling Pharmaceutical, Takeda, Tonghua Dongbao, Sanofi, Novo Nordisk, Merck, Eli Lilly and Jiangsu Wanbang, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Oral and Injectable Medications for Type 2 Diabetes, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Oral and Injectable Medications for Type 2 Diabetes, also provides the sales of main regions and countries. Of the upcoming market potential for Oral and Injectable Medications for Type 2 Diabetes, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Oral and Injectable Medications for Type 2 Diabetes sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Oral and Injectable Medications for Type 2 Diabetes market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Oral and Injectable Medications for Type 2 Diabetes sales, projected growth trends, production technology, application and end-user industry.

Oral and Injectable Medications for Type 2 Diabetes Segment by Company

United Laboratories

Yiling Pharmaceutical

Takeda

Tonghua Dongbao

Sanofi

Novo Nordisk

Merck

Eli Lilly

Jiangsu Wanbang

Jiangsu Hengrui Pharmaceuticals

Pfizer

Beijing Double-Crane Pharmaceutical

Huadong Medicine

Ganli Pharmaceutical

Beijing Beilu Pharmaceutical

bayer

AstraZeneca

Boehringer Ingelheim

Biocon

Oral and Injectable Medications for Type 2 Diabetes Segment by Type

Insulin

Biguanides

Sulfonylureas

SGLT2 Inhibitors

GLP‑1 Receptor Agonists

DPP‑4 Inhibitors

Others

Oral and Injectable Medications for Type 2 Diabetes Segment by Application

Clinic

Hospital

Pharmacy

Others

Oral and Injectable Medications for Type 2 Diabetes Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oral and Injectable Medications for Type 2 Diabetes market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Oral and Injectable Medications for Type 2 Diabetes and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oral and Injectable Medications for Type 2 Diabetes.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Oral and Injectable Medications for Type 2 Diabetes in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Oral and Injectable Medications for Type 2 Diabetes manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Oral and Injectable Medications for Type 2 Diabetes sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Oral and Injectable Medications for Type 2 Diabetes Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Insulin Major Manufacturers Table 3. Biguanides Major Manufacturers Table 4. Sulfonylureas Major Manufacturers Table 5. SGLT2 Inhibitors Major Manufacturers Table 6. GLP‑1 Receptor Agonists Major Manufacturers Table 7. DPP‑4 Inhibitors Major Manufacturers Table 8. Others Major Manufacturers Table 9. Global Oral and Injectable Medications for Type 2 Diabetes Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 10. Clinic Major Manufacturers Table 11. Hospital Major Manufacturers Table 12. Pharmacy Major Manufacturers Table 13. Others Major Manufacturers Table 14. Oral and Injectable Medications for Type 2 Diabetes Industry Trends Table 15. Oral and Injectable Medications for Type 2 Diabetes Industry Drivers Table 16. Oral and Injectable Medications for Type 2 Diabetes Industry Opportunities and Challenges Table 17. Oral and Injectable Medications for Type 2 Diabetes Industry Restraints Table 18. Global Oral and Injectable Medications for Type 2 Diabetes Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global Oral and Injectable Medications for Type 2 Diabetes Revenue by Region (2021-2026) & (US$ Million) Table 20. Global Oral and Injectable Medications for Type 2 Diabetes Revenue by Region (2027-2032) & (US$ Million) Table 21. Global Oral and Injectable Medications for Type 2 Diabetes Revenue Market Share by Region (2021-2026) Table 22. Global Oral and Injectable Medications for Type 2 Diabetes Revenue Market Share by Region (2027-2032) Table 23. Global Oral and Injectable Medications for Type 2 Diabetes Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (k units) Table 24. Global Oral and Injectable Medications for Type 2 Diabetes Sales by Region (2021-2026) & (k units) Table 25. Global Oral and Injectable Medications for Type 2 Diabetes Sales by Region (2027-2032) & (k units) Table 26. Global Oral and Injectable Medications for Type 2 Diabetes Sales Market Share by Region (2021-2026) Table 27. Global Oral and Injectable Medications for Type 2 Diabetes Sales Market Share by Region (2027-2032) Table 28. Global Oral and Injectable Medications for Type 2 Diabetes Revenue by Manufacturers (US$ Million) & (2021-2026) Table 29. Global Oral and Injectable Medications for Type 2 Diabetes Revenue Market Share by Manufacturers (2021-2026) Table 30. Global Oral and Injectable Medications for Type 2 Diabetes Sales by Manufacturers (US$ Million) & (2021-2026) Table 31. Global Oral and Injectable Medications for Type 2 Diabetes Sales Market Share by Manufacturers (2021-2026) Table 32. Global Oral and Injectable Medications for Type 2 Diabetes Sales Price (USD/unit) of Manufacturers (2021-2026) Table 33. Global Oral and Injectable Medications for Type 2 Diabetes Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 34. Global Oral and Injectable Medications for Type 2 Diabetes Key Manufacturers Manufacturing Sites & Headquarters Table 35. Global Oral and Injectable Medications for Type 2 Diabetes Manufacturers, Product Type & Application Table 36. Global Oral and Injectable Medications for Type 2 Diabetes Manufacturers' Establishment Date Table 37. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 38. Global Oral and Injectable Medications for Type 2 Diabetes by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 39. Global Oral and Injectable Medications for Type 2 Diabetes Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Oral and Injectable Medications for Type 2 Diabetes Revenue by Type (2021-2026) & (US$ Million) Table 41. Global Oral and Injectable Medications for Type 2 Diabetes Revenue by Type (2027-2032) & (US$ Million) Table 42. Global Oral and Injectable Medications for Type 2 Diabetes Revenue Market Share by Type (2021-2026) Table 43. Global Oral and Injectable Medications for Type 2 Diabetes Revenue Market Share by Type (2027-2032) Table 44. Global Oral and Injectable Medications for Type 2 Diabetes Sales by Type 2021 VS 2025 VS 2032 (k units) Table 45. Global Oral and Injectable Medications for Type 2 Diabetes Sales by Type (2021-2026) & (k units) Table 46. Global Oral and Injectable Medications for Type 2 Diabetes Sales by Type (2027-2032) & (k units) Table 47. Global Oral and Injectable Medications for Type 2 Diabetes Sales Market Share by Type (2021-2026) Table 48. Global Oral and Injectable Medications for Type 2 Diabetes Sales Market Share by Type (2027-2032) Table 49. Global Oral and Injectable Medications for Type 2 Diabetes Price by Type (2021-2026) & (USD/unit) Table 50. Global Oral and Injectable Medications for Type 2 Diabetes Price by Type (2027-2032) & (USD/unit) Table 51. Global Oral and Injectable Medications for Type 2 Diabetes Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 52. Global Oral and Injectable Medications for Type 2 Diabetes Revenue by Application (2021-2026) & (US$ Million) Table 53. Global Oral and Injectable Medications for Type 2 Diabetes Revenue by Application (2027-2032) & (US$ Million) Table 54. Global Oral and Injectable Medications for Type 2 Diabetes Revenue Market Share by Application (2021-2026) Table 55. Global Oral and Injectable Medications for Type 2 Diabetes Revenue Market Share by Application (2027-2032) Table 56. Global Oral and Injectable Medications for Type 2 Diabetes Sales by Application 2021 VS 2025 VS 2032 (k units) Table 57. Global Oral and Injectable Medications for Type 2 Diabetes Sales by Application (2021-2026) & (k units) Table 58. Global Oral and Injectable Medications for Type 2 Diabetes Sales by Application (2027-2032) & (k units) Table 59. Global Oral and Injectable Medications for Type 2 Diabetes Sales Market Share by Application (2021-2026) Table 60. Global Oral and Injectable Medications for Type 2 Diabetes Sales Market Share by Application (2027-2032) Table 61. Global Oral and Injectable Medications for Type 2 Diabetes Price by Application (2021-2026) & (USD/unit) Table 62. Global Oral and Injectable Medications for Type 2 Diabetes Price by Application (2027-2032) & (USD/unit) Table 63. United Laboratories Company Information Table 64. United Laboratories Business Overview Table 65. United Laboratories Oral and Injectable Medications for Type 2 Diabetes Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 66. United Laboratories Oral and Injectable Medications for Type 2 Diabetes Product Portfolio Table 67. United Laboratories Recent Development Table 68. Yiling Pharmaceutical Company Information Table 69. Yiling Pharmaceutical Business Overview Table 70. Yiling Pharmaceutical Oral and Injectable Medications for Type 2 Diabetes Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 71. Yiling Pharmaceutical Oral and Injectable Medications for Type 2 Diabetes Product Portfolio Table 72. Yiling Pharmaceutical Recent Development Table 73. Takeda Company Information Table 74. Takeda Business Overview Table 75. Takeda Oral and Injectable Medications for Type 2 Diabetes Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 76. Takeda Oral and Injectable Medications for Type 2 Diabetes Product Portfolio Table 77. Takeda Recent Development Table 78. Tonghua Dongbao Company Information Table 79. Tonghua Dongbao Business Overview Table 80. Tonghua Dongbao Oral and Injectable Medications for Type 2 Diabetes Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 81. Tonghua Dongbao Oral and Injectable Medications for Type 2 Diabetes Product Portfolio Table 82. Tonghua Dongbao Recent Development Table 83. Sanofi Company Information Table 84. Sanofi Business Overview Table 85. Sanofi Oral and Injectable Medications for Type 2 Diabetes Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 86. Sanofi Oral and Injectable Medications for Type 2 Diabetes Product Portfolio Table 87. Sanofi Recent Development Table 88. Novo Nordisk Company Information Table 89. Novo Nordisk Business Overview Table 90. Novo Nordisk Oral and Injectable Medications for Type 2 Diabetes Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 91. Novo Nordisk Oral and Injectable Medications for Type 2 Diabetes Product Portfolio Table 92. Novo Nordisk Recent Development Table 93. Merck Company Information Table 94. Merck Business Overview Table 95. Merck Oral and Injectable Medications for Type 2 Diabetes Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 96. Merck Oral and Injectable Medications for Type 2 Diabetes Product Portfolio Table 97. Merck Recent Development Table 98. Eli Lilly Company Information Table 99. Eli Lilly Business Overview Table 100. Eli Lilly Oral and Injectable Medications for Type 2 Diabetes Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 101. Eli Lilly Oral and Injectable Medications for Type 2 Diabetes Product Portfolio Table 102. Eli Lilly Recent Development Table 103. Jiangsu Wanbang Company Information Table 104. Jiangsu Wanbang Business Overview Table 105. Jiangsu Wanbang Oral and Injectable Medications for Type 2 Diabetes Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 106. Jiangsu Wanbang Oral and Injectable Medications for Type 2 Diabetes Product Portfolio Table 107. Jiangsu Wanbang Recent Development Table 108. Jiangsu Hengrui Pharmaceuticals Company Information Table 109. Jiangsu Hengrui Pharmaceuticals Business Overview Table 110. Jiangsu Hengrui Pharmaceuticals Oral and Injectable Medications for Type 2 Diabetes Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 111. Jiangsu Hengrui Pharmaceuticals Oral and Injectable Medications for Type 2 Diabetes Product Portfolio Table 112. Jiangsu Hengrui Pharmaceuticals Recent Development Table 113. Pfizer Company Information Table 114. Pfizer Business Overview Table 115. Pfizer Oral and Injectable Medications for Type 2 Diabetes Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 116. Pfizer Oral and Injectable Medications for Type 2 Diabetes Product Portfolio Table 117. Pfizer Recent Development Table 118. Beijing Double-Crane Pharmaceutical Company Information Table 119. Beijing Double-Crane Pharmaceutical Business Overview Table 120. Beijing Double-Crane Pharmaceutical Oral and Injectable Medications for Type 2 Diabetes Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 121. Beijing Double-Crane Pharmaceutical Oral and Injectable Medications for Type 2 Diabetes Product Portfolio Table 122. Beijing Double-Crane Pharmaceutical Recent Development Table 123. Huadong Medicine Company Information Table 124. Huadong Medicine Business Overview Table 125. Huadong Medicine Oral and Injectable Medications for Type 2 Diabetes Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 126. Huadong Medicine Oral and Injectable Medications for Type 2 Diabetes Product Portfolio Table 127. Huadong Medicine Recent Development Table 128. Ganli Pharmaceutical Company Information Table 129. Ganli Pharmaceutical Business Overview Table 130. Ganli Pharmaceutical Oral and Injectable Medications for Type 2 Diabetes Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 131. Ganli Pharmaceutical Oral and Injectable Medications for Type 2 Diabetes Product Portfolio Table 132. Ganli Pharmaceutical Recent Development Table 133. Beijing Beilu Pharmaceutical Company Information Table 134. Beijing Beilu Pharmaceutical Business Overview Table 135. Beijing Beilu Pharmaceutical Oral and Injectable Medications for Type 2 Diabetes Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 136. Beijing Beilu Pharmaceutical Oral and Injectable Medications for Type 2 Diabetes Product Portfolio Table 137. Beijing Beilu Pharmaceutical Recent Development Table 138. bayer Company Information Table 139. bayer Business Overview Table 140. bayer Oral and Injectable Medications for Type 2 Diabetes Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 141. bayer Oral and Injectable Medications for Type 2 Diabetes Product Portfolio Table 142. bayer Recent Development Table 143. AstraZeneca Company Information Table 144. AstraZeneca Business Overview Table 145. AstraZeneca Oral and Injectable Medications for Type 2 Diabetes Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 146. AstraZeneca Oral and Injectable Medications for Type 2 Diabetes Product Portfolio Table 147. AstraZeneca Recent Development Table 148. Boehringer Ingelheim Company Information Table 149. Boehringer Ingelheim Business Overview Table 150. Boehringer Ingelheim Oral and Injectable Medications for Type 2 Diabetes Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 151. Boehringer Ingelheim Oral and Injectable Medications for Type 2 Diabetes Product Portfolio Table 152. Boehringer Ingelheim Recent Development Table 153. Biocon Company Information Table 154. Biocon Business Overview Table 155. Biocon Oral and Injectable Medications for Type 2 Diabetes Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 156. Biocon Oral and Injectable Medications for Type 2 Diabetes Product Portfolio Table 157. Biocon Recent Development Table 158. North America Oral and Injectable Medications for Type 2 Diabetes Revenue by Type (2021-2026) & (US$ Million) Table 159. North America Oral and Injectable Medications for Type 2 Diabetes Revenue by Type (2027-2032) & (US$ Million) Table 160. North America Oral and Injectable Medications for Type 2 Diabetes Sales by Type (2021-2026) & (k units) Table 161. North America Oral and Injectable Medications for Type 2 Diabetes Sales by Type (2027-2032) & (k units) Table 162. North America Oral and Injectable Medications for Type 2 Diabetes Sales Price by Type (2021-2026) & (USD/unit) Table 163. North America Oral and Injectable Medications for Type 2 Diabetes Sales Price by Type (2027-2032) & (USD/unit) Table 164. North America Oral and Injectable Medications for Type 2 Diabetes Revenue by Application (2021-2026) & (US$ Million) Table 165. North America Oral and Injectable Medications for Type 2 Diabetes Revenue by Application (2027-2032) & (US$ Million) Table 166. North America Oral and Injectable Medications for Type 2 Diabetes Sales by Application (2021-2026) & (k units) Table 167. North America Oral and Injectable Medications for Type 2 Diabetes Sales by Application (2027-2032) & (k units) Table 168. North America Oral and Injectable Medications for Type 2 Diabetes Sales Price by Application (2021-2026) & (USD/unit) Table 169. North America Oral and Injectable Medications for Type 2 Diabetes Sales Price by Application (2027-2032) & (USD/unit) Table 170. North America Oral and Injectable Medications for Type 2 Diabetes Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 171. North America Oral and Injectable Medications for Type 2 Diabetes Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 172. North America Oral and Injectable Medications for Type 2 Diabetes Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 173. North America Oral and Injectable Medications for Type 2 Diabetes Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 174. North America Oral and Injectable Medications for Type 2 Diabetes Sales by Country (2021-2026) & (k units) Table 175. North America Oral and Injectable Medications for Type 2 Diabetes Sales by Country (2027-2032) & (k units) Table 176. North America Oral and Injectable Medications for Type 2 Diabetes Sales Price by Country (2021-2026) & (USD/unit) Table 177. North America Oral and Injectable Medications for Type 2 Diabetes Sales Price by Country (2027-2032) & (USD/unit) Table 178. United States Oral and Injectable Medications for Type 2 Diabetes Revenue (2021-2032) & (US$ Million) Table 179. Canada Oral and Injectable Medications for Type 2 Diabetes Revenue (2021-2032) & (US$ Million) Table 180. Mexico Oral and Injectable Medications for Type 2 Diabetes Revenue (2021-2032) & (US$ Million) Table 181. Europe Oral and Injectable Medications for Type 2 Diabetes Revenue by Type (2021-2026) & (US$ Million) Table 182. Europe Oral and Injectable Medications for Type 2 Diabetes Revenue by Type (2027-2032) & (US$ Million) Table 183. Europe Oral and Injectable Medications for Type 2 Diabetes Sales by Type (2021-2026) & (k units) Table 184. Europe Oral and Injectable Medications for Type 2 Diabetes Sales by Type (2027-2032) & (k units) Table 185. Europe Oral and Injectable Medications for Type 2 Diabetes Sales Price by Type (2021-2026) & (USD/unit) Table 186. Europe Oral and Injectable Medications for Type 2 Diabetes Sales Price by Type (2027-2032) & (USD/unit) Table 187. Europe Oral and Injectable Medications for Type 2 Diabetes Revenue by Application (2021-2026) & (US$ Million) Table 188. Europe Oral and Injectable Medications for Type 2 Diabetes Revenue by Application (2027-2032) & (US$ Million) Table 189. Europe Oral and Injectable Medications for Type 2 Diabetes Sales by Application (2021-2026) & (k units) Table 190. Europe Oral and Injectable Medications for Type 2 Diabetes Sales by Application (2027-2032) & (k units) Table 191. Europe Oral and Injectable Medications for Type 2 Diabetes Sales Price by Application (2021-2026) & (USD/unit) Table 192. Europe Oral and Injectable Medications for Type 2 Diabetes Sales Price by Application (2027-2032) & (USD/unit) Table 193. Europe Oral and Injectable Medications for Type 2 Diabetes Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 194. Europe Oral and Injectable Medications for Type 2 Diabetes Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 195. Europe Oral and Injectable Medications for Type 2 Diabetes Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 196. Europe Oral and Injectable Medications for Type 2 Diabetes Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 197. Europe Oral and Injectable Medications for Type 2 Diabetes Sales by Country (2021-2026) & (k units) Table 198. Europe Oral and Injectable Medications for Type 2 Diabetes Sales by Country (2027-2032) & (k units) Table 199. Europe Oral and Injectable Medications for Type 2 Diabetes Sales Price by Country (2021-2026) & (USD/unit) Table 200. Europe Oral and Injectable Medications for Type 2 Diabetes Sales Price by Country (2027-2032) & (USD/unit) Table 201. Germany Oral and Injectable Medications for Type 2 Diabetes Revenue (2021-2032) & (US$ Million) Table 202. France Oral and Injectable Medications for Type 2 Diabetes Revenue (2021-2032) & (US$ Million) Table 203. U.K. Oral and Injectable Medications for Type 2 Diabetes Revenue (2021-2032) & (US$ Million) Table 204. Italy Oral and Injectable Medications for Type 2 Diabetes Revenue (2021-2032) & (US$ Million) Table 205. Russia Oral and Injectable Medications for Type 2 Diabetes Revenue (2021-2032) & (US$ Million) Table 206. Spain Oral and Injectable Medications for Type 2 Diabetes Revenue (2021-2032) & (US$ Million) Table 207. Netherlands Oral and Injectable Medications for Type 2 Diabetes Revenue (2021-2032) & (US$ Million) Table 208. Switzerland Oral and Injectable Medications for Type 2 Diabetes Revenue (2021-2032) & (US$ Million) Table 209. Sweden Oral and Injectable Medications for Type 2 Diabetes Revenue (2021-2032) & (US$ Million) Table 210. Poland Oral and Injectable Medications for Type 2 Diabetes Revenue (2021-2032) & (US$ Million) Table 211. China Oral and Injectable Medications for Type 2 Diabetes Revenue by Type (2021-2026) & (US$ Million) Table 212. China Oral and Injectable Medications for Type 2 Diabetes Revenue by Type (2027-2032) & (US$ Million) Table 213. China Oral and Injectable Medications for Type 2 Diabetes Sales by Type (2021-2026) & (k units) Table 214. China Oral and Injectable Medications for Type 2 Diabetes Sales by Type (2027-2032) & (k units) Table 215. China Oral and Injectable Medications for Type 2 Diabetes Sales Price by Type (2021-2026) & (USD/unit) Table 216. China Oral and Injectable Medications for Type 2 Diabetes Sales Price by Type (2027-2032) & (USD/unit) Table 217. China Oral and Injectable Medications for Type 2 Diabetes Revenue by Application (2021-2026) & (US$ Million) Table 218. China Oral and Injectable Medications for Type 2 Diabetes Revenue by Application (2027-2032) & (US$ Million) Table 219. China Oral and Injectable Medications for Type 2 Diabetes Sales by Application (2021-2026) & (k units) Table 220. China Oral and Injectable Medications for Type 2 Diabetes Sales by Application (2027-2032) & (k units) Table 221. China Oral and Injectable Medications for Type 2 Diabetes Sales Price by Application (2021-2026) & (USD/unit) Table 222. China Oral and Injectable Medications for Type 2 Diabetes Sales Price by Application (2027-2032) & (USD/unit) Table 223. Asia Oral and Injectable Medications for Type 2 Diabetes Revenue by Type (2021-2026) & (US$ Million) Table 224. Asia Oral and Injectable Medications for Type 2 Diabetes Revenue by Type (2027-2032) & (US$ Million) Table 225. Asia Oral and Injectable Medications for Type 2 Diabetes Sales by Type (2021-2026) & (k units) Table 226. Asia Oral and Injectable Medications for Type 2 Diabetes Sales by Type (2027-2032) & (k units) Table 227. Asia Oral and Injectable Medications for Type 2 Diabetes Sales Price by Type (2021-2026) & (USD/unit) Table 228. Asia Oral and Injectable Medications for Type 2 Diabetes Sales Price by Type (2027-2032) & (USD/unit) Table 229. Asia Oral and Injectable Medications for Type 2 Diabetes Revenue by Application (2021-2026) & (US$ Million) Table 230. Asia Oral and Injectable Medications for Type 2 Diabetes Revenue by Application (2027-2032) & (US$ Million) Table 231. Asia Oral and Injectable Medications for Type 2 Diabetes Sales by Application (2021-2026) & (k units) Table 232. Asia Oral and Injectable Medications for Type 2 Diabetes Sales by Application (2027-2032) & (k units) Table 233. Asia Oral and Injectable Medications for Type 2 Diabetes Sales Price by Application (2021-2026) & (USD/unit) Table 234. Asia Oral and Injectable Medications for Type 2 Diabetes Sales Price by Application (2027-2032) & (USD/unit) Table 235. Asia Oral and Injectable Medications for Type 2 Diabetes Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 236. Asia Oral and Injectable Medications for Type 2 Diabetes Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 237. Asia Oral and Injectable Medications for Type 2 Diabetes Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 238. Asia Oral and Injectable Medications for Type 2 Diabetes Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 239. Asia Oral and Injectable Medications for Type 2 Diabetes Sales by Country (2021-2026) & (k units) Table 240. Asia Oral and Injectable Medications for Type 2 Diabetes Sales by Country (2027-2032) & (k units) Table 241. Asia Oral and Injectable Medications for Type 2 Diabetes Sales Price by Country (2021-2026) & (USD/unit) Table 242. Asia Oral and Injectable Medications for Type 2 Diabetes Sales Price by Country (2027-2032) & (USD/unit) Table 243. Japan Oral and Injectable Medications for Type 2 Diabetes Revenue (2021-2032) & (US$ Million) Table 244. South Korea Oral and Injectable Medications for Type 2 Diabetes Revenue (2021-2032) & (US$ Million) Table 245. India Oral and Injectable Medications for Type 2 Diabetes Revenue (2021-2032) & (US$ Million) Table 246. Australia Oral and Injectable Medications for Type 2 Diabetes Revenue (2021-2032) & (US$ Million) Table 247. Taiwan Oral and Injectable Medications for Type 2 Diabetes Revenue (2021-2032) & (US$ Million) Table 248. Southeast Asia Oral and Injectable Medications for Type 2 Diabetes Revenue (2021-2032) & (US$ Million) Table 249. SAMEA Oral and Injectable Medications for Type 2 Diabetes Revenue by Type (2021-2026) & (US$ Million) Table 250. SAMEA Oral and Injectable Medications for Type 2 Diabetes Revenue by Type (2027-2032) & (US$ Million) Table 251. SAMEA Oral and Injectable Medications for Type 2 Diabetes Sales by Type (2021-2026) & (k units) Table 252. SAMEA Oral and Injectable Medications for Type 2 Diabetes Sales by Type (2027-2032) & (k units) Table 253. SAMEA Oral and Injectable Medications for Type 2 Diabetes Sales Price by Type (2021-2026) & (USD/unit) Table 254. SAMEA Oral and Injectable Medications for Type 2 Diabetes Sales Price by Type (2027-2032) & (USD/unit) Table 255. SAMEA Oral and Injectable Medications for Type 2 Diabetes Revenue by Application (2021-2026) & (US$ Million) Table 256. SAMEA Oral and Injectable Medications for Type 2 Diabetes Revenue by Application (2027-2032) & (US$ Million) Table 257. SAMEA Oral and Injectable Medications for Type 2 Diabetes Sales by Application (2021-2026) & (k units) Table 258. SAMEA Oral and Injectable Medications for Type 2 Diabetes Sales by Application (2027-2032) & (k units) Table 259. SAMEA Oral and Injectable Medications for Type 2 Diabetes Sales Price by Application (2021-2026) & (USD/unit) Table 260. SAMEA Oral and Injectable Medications for Type 2 Diabetes Sales Price by Application (2027-2032) & (USD/unit) Table 261. SAMEA Oral and Injectable Medications for Type 2 Diabetes Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 262. SAMEA Oral and Injectable Medications for Type 2 Diabetes Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 263. SAMEA Oral and Injectable Medications for Type 2 Diabetes Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 264. SAMEA Oral and Injectable Medications for Type 2 Diabetes Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 265. SAMEA Oral and Injectable Medications for Type 2 Diabetes Sales by Country (2021-2026) & (k units) Table 266. SAMEA Oral and Injectable Medications for Type 2 Diabetes Sales by Country (2027-2032) & (k units) Table 267. SAMEA Oral and Injectable Medications for Type 2 Diabetes Sales Price by Country (2021-2026) & (USD/unit) Table 268. SAMEA Oral and Injectable Medications for Type 2 Diabetes Sales Price by Country (2027-2032) & (USD/unit) Table 269. Brazil Oral and Injectable Medications for Type 2 Diabetes Revenue (2021-2032) & (US$ Million) Table 270. Argentina Oral and Injectable Medications for Type 2 Diabetes Revenue (2021-2032) & (US$ Million) Table 271. Chile Oral and Injectable Medications for Type 2 Diabetes Revenue (2021-2032) & (US$ Million) Table 272. Colombia Oral and Injectable Medications for Type 2 Diabetes Revenue (2021-2032) & (US$ Million) Table 273. Peru Oral and Injectable Medications for Type 2 Diabetes Revenue (2021-2032) & (US$ Million) Table 274. Saudi Arabia Oral and Injectable Medications for Type 2 Diabetes Revenue (2021-2032) & (US$ Million) Table 275. Israel Oral and Injectable Medications for Type 2 Diabetes Revenue (2021-2032) & (US$ Million) Table 276. UAE Oral and Injectable Medications for Type 2 Diabetes Revenue (2021-2032) & (US$ Million) Table 277. Turkey Oral and Injectable Medications for Type 2 Diabetes Revenue (2021-2032) & (US$ Million) Table 278. Iran Oral and Injectable Medications for Type 2 Diabetes Revenue (2021-2032) & (US$ Million) Table 279. Egypt Oral and Injectable Medications for Type 2 Diabetes Revenue (2021-2032) & (US$ Million) Table 280. Key Raw Materials Table 281. Raw Materials Key Suppliers Table 282. Oral and Injectable Medications for Type 2 Diabetes Distributors List Table 283. Oral and Injectable Medications for Type 2 Diabetes Customers List Table 284. Research Programs/Design for This Report Table 285. Authors List of This Report Table 286. Secondary Sources Table 287. Primary Sources List of Figures Figure 1. Oral and Injectable Medications for Type 2 Diabetes Image Figure 2. Global Oral and Injectable Medications for Type 2 Diabetes Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Oral and Injectable Medications for Type 2 Diabetes Market Size Share 2021 VS 2025 VS 2032 Figure 4. Insulin Image Figure 5. Biguanides Image Figure 6. Sulfonylureas Image Figure 7. SGLT2 Inhibitors Image Figure 8. GLP‑1 Receptor Agonists Image Figure 9. DPP‑4 Inhibitors Image Figure 10. Others Image Figure 11. Global Oral and Injectable Medications for Type 2 Diabetes Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global Oral and Injectable Medications for Type 2 Diabetes Market Size Share 2021 VS 2025 VS 2032 Figure 13. Clinic Image Figure 14. Hospital Image Figure 15. Pharmacy Image Figure 16. Others Image Figure 17. Global Oral and Injectable Medications for Type 2 Diabetes Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 18. Global Oral and Injectable Medications for Type 2 Diabetes Revenue (2021-2032) & (US$ Million) Figure 19. Global Oral and Injectable Medications for Type 2 Diabetes Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Oral and Injectable Medications for Type 2 Diabetes Revenue Market Share by Region: 2025 Versus 2032 Figure 21. Global Oral and Injectable Medications for Type 2 Diabetes Revenue Market Share by Region (2021-2032) Figure 22. Global Oral and Injectable Medications for Type 2 Diabetes Sales (2021-2032) & (k units) Figure 23. Global Oral and Injectable Medications for Type 2 Diabetes Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 24. Global Oral and Injectable Medications for Type 2 Diabetes Sales Market Share by Region (2021-2032) Figure 25. US & Canada & Mexico Oral and Injectable Medications for Type 2 Diabetes Sales YoY (2021-2032) & (k units) Figure 26. Europe Oral and Injectable Medications for Type 2 Diabetes Sales YoY (2021-2032) & (k units) Figure 27. China Oral and Injectable Medications for Type 2 Diabetes Sales YoY (2021-2032) & (k units) Figure 28. Asia (Excluding China) Oral and Injectable Medications for Type 2 Diabetes Sales YoY (2021-2032) & (k units) Figure 29. South America, Middle East and Africa Oral and Injectable Medications for Type 2 Diabetes Sales YoY (2021-2032) & (k units) Figure 30. Global Oral and Injectable Medications for Type 2 Diabetes Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 31. Global Oral and Injectable Medications for Type 2 Diabetes Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 32. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 33. Global Oral and Injectable Medications for Type 2 Diabetes Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million)

Scope & coverage.

Types
  • Insulin
  • Biguanides
  • Sulfonylureas
  • SGLT2 Inhibitors
  • GLP‑1 Receptor Agonists
  • DPP‑4 Inhibitors
  • Others
Applications
  • Clinic
  • Hospital
  • Pharmacy
  • Others
Companies covered
  • United Laboratories
  • Yiling Pharmaceutical
  • Takeda
  • Tonghua Dongbao
  • Sanofi
  • Novo Nordisk
  • Merck
  • Eli Lilly
  • Jiangsu Wanbang
  • Jiangsu Hengrui Pharmaceuticals
  • Pfizer
  • Beijing Double-Crane Pharmaceutical
  • Huadong Medicine
  • Ganli Pharmaceutical
  • Beijing Beilu Pharmaceutical
  • bayer
  • AstraZeneca
  • Boehringer Ingelheim
  • Biocon

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Oral and Injectable Medications for Type 2 Diabetes Market by Type
  3. 1.2.1 Global Oral and Injectable Medications for Type 2 Diabetes Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Insulin
  5. 1.2.3 Biguanides
  6. 1.2.4 Sulfonylureas
  7. 1.2.5 SGLT2 Inhibitors
  8. 1.2.6 GLP‑1 Receptor Agonists
  9. 1.2.7 DPP‑4 Inhibitors
  10. 1.2.8 Others
  11. 1.3 Oral and Injectable Medications for Type 2 Diabetes Market by Application
  12. 1.3.1 Global Oral and Injectable Medications for Type 2 Diabetes Market Size by Application, 2021 VS 2025 VS 2032
  13. 1.3.2 Clinic
  14. 1.3.3 Hospital
  15. 1.3.4 Pharmacy
  16. 1.3.5 Others
  17. 1.4 Assumptions and Limitations
  18. 1.5 Study Goals and Objectives
2 Oral and Injectable Medications for Type 2 Diabetes Market Dynamics
  1. 2.1 Oral and Injectable Medications for Type 2 Diabetes Industry Trends
  2. 2.2 Oral and Injectable Medications for Type 2 Diabetes Industry Drivers
  3. 2.3 Oral and Injectable Medications for Type 2 Diabetes Industry Opportunities and Challenges
  4. 2.4 Oral and Injectable Medications for Type 2 Diabetes Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Oral and Injectable Medications for Type 2 Diabetes Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Oral and Injectable Medications for Type 2 Diabetes Revenue by Region
  3. 3.2.1 Global Oral and Injectable Medications for Type 2 Diabetes Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Oral and Injectable Medications for Type 2 Diabetes Revenue by Region (2021-2026)
  5. 3.2.3 Global Oral and Injectable Medications for Type 2 Diabetes Revenue by Region (2027-2032)
  6. 3.2.4 Global Oral and Injectable Medications for Type 2 Diabetes Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Oral and Injectable Medications for Type 2 Diabetes Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Oral and Injectable Medications for Type 2 Diabetes Sales by Region
  9. 3.4.1 Global Oral and Injectable Medications for Type 2 Diabetes Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Oral and Injectable Medications for Type 2 Diabetes Sales by Region (2021-2026)
  11. 3.4.3 Global Oral and Injectable Medications for Type 2 Diabetes Sales by Region (2027-2032)
  12. 3.4.4 Global Oral and Injectable Medications for Type 2 Diabetes Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Oral and Injectable Medications for Type 2 Diabetes Revenue by Manufacturers
  2. 4.1.1 Global Oral and Injectable Medications for Type 2 Diabetes Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Oral and Injectable Medications for Type 2 Diabetes Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Oral and Injectable Medications for Type 2 Diabetes Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Oral and Injectable Medications for Type 2 Diabetes Sales by Manufacturers
  6. 4.2.1 Global Oral and Injectable Medications for Type 2 Diabetes Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Oral and Injectable Medications for Type 2 Diabetes Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Oral and Injectable Medications for Type 2 Diabetes Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Oral and Injectable Medications for Type 2 Diabetes Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Oral and Injectable Medications for Type 2 Diabetes Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Oral and Injectable Medications for Type 2 Diabetes Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Oral and Injectable Medications for Type 2 Diabetes Manufacturers, Product Type & Application
  13. 4.7 Global Oral and Injectable Medications for Type 2 Diabetes Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Oral and Injectable Medications for Type 2 Diabetes Market CR5 and HHI
  16. 4.8.2 2025 Oral and Injectable Medications for Type 2 Diabetes Tier 1, Tier 2, and Tier 3
5 Oral and Injectable Medications for Type 2 Diabetes Market by Type
  1. 5.1 Global Oral and Injectable Medications for Type 2 Diabetes Revenue by Type
  2. 5.1.1 Global Oral and Injectable Medications for Type 2 Diabetes Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Oral and Injectable Medications for Type 2 Diabetes Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Oral and Injectable Medications for Type 2 Diabetes Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Oral and Injectable Medications for Type 2 Diabetes Sales by Type
  6. 5.2.1 Global Oral and Injectable Medications for Type 2 Diabetes Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Oral and Injectable Medications for Type 2 Diabetes Sales by Type (2021-2032) & (k units)
  8. 5.2.3 Global Oral and Injectable Medications for Type 2 Diabetes Sales Market Share by Type (2021-2032)
  9. 5.3 Global Oral and Injectable Medications for Type 2 Diabetes Price by Type
6 Oral and Injectable Medications for Type 2 Diabetes Market by Application
  1. 6.1 Global Oral and Injectable Medications for Type 2 Diabetes Revenue by Application
  2. 6.1.1 Global Oral and Injectable Medications for Type 2 Diabetes Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Oral and Injectable Medications for Type 2 Diabetes Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Oral and Injectable Medications for Type 2 Diabetes Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Oral and Injectable Medications for Type 2 Diabetes Sales by Application
  6. 6.2.1 Global Oral and Injectable Medications for Type 2 Diabetes Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Oral and Injectable Medications for Type 2 Diabetes Sales by Application (2021-2032) & (k units)
  8. 6.2.3 Global Oral and Injectable Medications for Type 2 Diabetes Sales Market Share by Application (2021-2032)
  9. 6.3 Global Oral and Injectable Medications for Type 2 Diabetes Price by Application
7 Company Profiles
  1. 7.1 United Laboratories
  2. 7.1.1 United Laboratories Company Information
  3. 7.1.2 United Laboratories Business Overview
  4. 7.1.3 United Laboratories Oral and Injectable Medications for Type 2 Diabetes Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 United Laboratories Oral and Injectable Medications for Type 2 Diabetes Product Portfolio
  6. 7.1.5 United Laboratories Recent Developments
  7. 7.2 Yiling Pharmaceutical
  8. 7.2.1 Yiling Pharmaceutical Company Information
  9. 7.2.2 Yiling Pharmaceutical Business Overview
  10. 7.2.3 Yiling Pharmaceutical Oral and Injectable Medications for Type 2 Diabetes Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Yiling Pharmaceutical Oral and Injectable Medications for Type 2 Diabetes Product Portfolio
  12. 7.2.5 Yiling Pharmaceutical Recent Developments
  13. 7.3 Takeda
  14. 7.3.1 Takeda Company Information
  15. 7.3.2 Takeda Business Overview
  16. 7.3.3 Takeda Oral and Injectable Medications for Type 2 Diabetes Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Takeda Oral and Injectable Medications for Type 2 Diabetes Product Portfolio
  18. 7.3.5 Takeda Recent Developments
  19. 7.4 Tonghua Dongbao
  20. 7.4.1 Tonghua Dongbao Company Information
  21. 7.4.2 Tonghua Dongbao Business Overview
  22. 7.4.3 Tonghua Dongbao Oral and Injectable Medications for Type 2 Diabetes Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Tonghua Dongbao Oral and Injectable Medications for Type 2 Diabetes Product Portfolio
  24. 7.4.5 Tonghua Dongbao Recent Developments
  25. 7.5 Sanofi
  26. 7.5.1 Sanofi Company Information
  27. 7.5.2 Sanofi Business Overview
  28. 7.5.3 Sanofi Oral and Injectable Medications for Type 2 Diabetes Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Sanofi Oral and Injectable Medications for Type 2 Diabetes Product Portfolio
  30. 7.5.5 Sanofi Recent Developments
  31. 7.6 Novo Nordisk
  32. 7.6.1 Novo Nordisk Company Information
  33. 7.6.2 Novo Nordisk Business Overview
  34. 7.6.3 Novo Nordisk Oral and Injectable Medications for Type 2 Diabetes Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Novo Nordisk Oral and Injectable Medications for Type 2 Diabetes Product Portfolio
  36. 7.6.5 Novo Nordisk Recent Developments
  37. 7.7 Merck
  38. 7.7.1 Merck Company Information
  39. 7.7.2 Merck Business Overview
  40. 7.7.3 Merck Oral and Injectable Medications for Type 2 Diabetes Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Merck Oral and Injectable Medications for Type 2 Diabetes Product Portfolio
  42. 7.7.5 Merck Recent Developments
  43. 7.8 Eli Lilly
  44. 7.8.1 Eli Lilly Company Information
  45. 7.8.2 Eli Lilly Business Overview
  46. 7.8.3 Eli Lilly Oral and Injectable Medications for Type 2 Diabetes Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Eli Lilly Oral and Injectable Medications for Type 2 Diabetes Product Portfolio
  48. 7.8.5 Eli Lilly Recent Developments
  49. 7.9 Jiangsu Wanbang
  50. 7.9.1 Jiangsu Wanbang Company Information
  51. 7.9.2 Jiangsu Wanbang Business Overview
  52. 7.9.3 Jiangsu Wanbang Oral and Injectable Medications for Type 2 Diabetes Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Jiangsu Wanbang Oral and Injectable Medications for Type 2 Diabetes Product Portfolio
  54. 7.9.5 Jiangsu Wanbang Recent Developments
  55. 7.10 Jiangsu Hengrui Pharmaceuticals
  56. 7.10.1 Jiangsu Hengrui Pharmaceuticals Company Information
  57. 7.10.2 Jiangsu Hengrui Pharmaceuticals Business Overview
  58. 7.10.3 Jiangsu Hengrui Pharmaceuticals Oral and Injectable Medications for Type 2 Diabetes Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Jiangsu Hengrui Pharmaceuticals Oral and Injectable Medications for Type 2 Diabetes Product Portfolio
  60. 7.10.5 Jiangsu Hengrui Pharmaceuticals Recent Developments
  61. 7.11 Pfizer
  62. 7.11.1 Pfizer Company Information
  63. 7.11.2 Pfizer Business Overview
  64. 7.11.3 Pfizer Oral and Injectable Medications for Type 2 Diabetes Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 Pfizer Oral and Injectable Medications for Type 2 Diabetes Product Portfolio
  66. 7.11.5 Pfizer Recent Developments
  67. 7.12 Beijing Double-Crane Pharmaceutical
  68. 7.12.1 Beijing Double-Crane Pharmaceutical Company Information
  69. 7.12.2 Beijing Double-Crane Pharmaceutical Business Overview
  70. 7.12.3 Beijing Double-Crane Pharmaceutical Oral and Injectable Medications for Type 2 Diabetes Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 Beijing Double-Crane Pharmaceutical Oral and Injectable Medications for Type 2 Diabetes Product Portfolio
  72. 7.12.5 Beijing Double-Crane Pharmaceutical Recent Developments
  73. 7.13 Huadong Medicine
  74. 7.13.1 Huadong Medicine Company Information
  75. 7.13.2 Huadong Medicine Business Overview
  76. 7.13.3 Huadong Medicine Oral and Injectable Medications for Type 2 Diabetes Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 Huadong Medicine Oral and Injectable Medications for Type 2 Diabetes Product Portfolio
  78. 7.13.5 Huadong Medicine Recent Developments
  79. 7.14 Ganli Pharmaceutical
  80. 7.14.1 Ganli Pharmaceutical Company Information
  81. 7.14.2 Ganli Pharmaceutical Business Overview
  82. 7.14.3 Ganli Pharmaceutical Oral and Injectable Medications for Type 2 Diabetes Sales, Revenue, Price and Gross Margin (2021-2026)
  83. 7.14.4 Ganli Pharmaceutical Oral and Injectable Medications for Type 2 Diabetes Product Portfolio
  84. 7.14.5 Ganli Pharmaceutical Recent Developments
  85. 7.15 Beijing Beilu Pharmaceutical
  86. 7.15.1 Beijing Beilu Pharmaceutical Company Information
  87. 7.15.2 Beijing Beilu Pharmaceutical Business Overview
  88. 7.15.3 Beijing Beilu Pharmaceutical Oral and Injectable Medications for Type 2 Diabetes Sales, Revenue, Price and Gross Margin (2021-2026)
  89. 7.15.4 Beijing Beilu Pharmaceutical Oral and Injectable Medications for Type 2 Diabetes Product Portfolio
  90. 7.15.5 Beijing Beilu Pharmaceutical Recent Developments
  91. 7.16 bayer
  92. 7.16.1 bayer Company Information
  93. 7.16.2 bayer Business Overview
  94. 7.16.3 bayer Oral and Injectable Medications for Type 2 Diabetes Sales, Revenue, Price and Gross Margin (2021-2026)
  95. 7.16.4 bayer Oral and Injectable Medications for Type 2 Diabetes Product Portfolio
  96. 7.16.5 bayer Recent Developments
  97. 7.17 AstraZeneca
  98. 7.17.1 AstraZeneca Company Information
  99. 7.17.2 AstraZeneca Business Overview
  100. 7.17.3 AstraZeneca Oral and Injectable Medications for Type 2 Diabetes Sales, Revenue, Price and Gross Margin (2021-2026)
  101. 7.17.4 AstraZeneca Oral and Injectable Medications for Type 2 Diabetes Product Portfolio
  102. 7.17.5 AstraZeneca Recent Developments
  103. 7.18 Boehringer Ingelheim
  104. 7.18.1 Boehringer Ingelheim Company Information
  105. 7.18.2 Boehringer Ingelheim Business Overview
  106. 7.18.3 Boehringer Ingelheim Oral and Injectable Medications for Type 2 Diabetes Sales, Revenue, Price and Gross Margin (2021-2026)
  107. 7.18.4 Boehringer Ingelheim Oral and Injectable Medications for Type 2 Diabetes Product Portfolio
  108. 7.18.5 Boehringer Ingelheim Recent Developments
  109. 7.19 Biocon
  110. 7.19.1 Biocon Company Information
  111. 7.19.2 Biocon Business Overview
  112. 7.19.3 Biocon Oral and Injectable Medications for Type 2 Diabetes Sales, Revenue, Price and Gross Margin (2021-2026)
  113. 7.19.4 Biocon Oral and Injectable Medications for Type 2 Diabetes Product Portfolio
  114. 7.19.5 Biocon Recent Developments
8 North America
  1. 8.1 North America Oral and Injectable Medications for Type 2 Diabetes Market Size by Type
  2. 8.1.1 North America Oral and Injectable Medications for Type 2 Diabetes Revenue by Type (2021-2032)
  3. 8.1.2 North America Oral and Injectable Medications for Type 2 Diabetes Sales by Type (2021-2032)
  4. 8.1.3 North America Oral and Injectable Medications for Type 2 Diabetes Price by Type (2021-2032)
  5. 8.2 North America Oral and Injectable Medications for Type 2 Diabetes Market Size by Application
  6. 8.2.1 North America Oral and Injectable Medications for Type 2 Diabetes Revenue by Application (2021-2032)
  7. 8.2.2 North America Oral and Injectable Medications for Type 2 Diabetes Sales by Application (2021-2032)
  8. 8.2.3 North America Oral and Injectable Medications for Type 2 Diabetes Price by Application (2021-2032)
  9. 8.3 North America Oral and Injectable Medications for Type 2 Diabetes Market Size by Country
  10. 8.3.1 North America Oral and Injectable Medications for Type 2 Diabetes Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Oral and Injectable Medications for Type 2 Diabetes Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Oral and Injectable Medications for Type 2 Diabetes Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Oral and Injectable Medications for Type 2 Diabetes Market Size by Type
  2. 9.1.1 Europe Oral and Injectable Medications for Type 2 Diabetes Revenue by Type (2021-2032)
  3. 9.1.2 Europe Oral and Injectable Medications for Type 2 Diabetes Sales by Type (2021-2032)
  4. 9.1.3 Europe Oral and Injectable Medications for Type 2 Diabetes Price by Type (2021-2032)
  5. 9.2 Europe Oral and Injectable Medications for Type 2 Diabetes Market Size by Application
  6. 9.2.1 Europe Oral and Injectable Medications for Type 2 Diabetes Revenue by Application (2021-2032)
  7. 9.2.2 Europe Oral and Injectable Medications for Type 2 Diabetes Sales by Application (2021-2032)
  8. 9.2.3 Europe Oral and Injectable Medications for Type 2 Diabetes Price by Application (2021-2032)
  9. 9.3 Europe Oral and Injectable Medications for Type 2 Diabetes Market Size by Country
  10. 9.3.1 Europe Oral and Injectable Medications for Type 2 Diabetes Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Oral and Injectable Medications for Type 2 Diabetes Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Oral and Injectable Medications for Type 2 Diabetes Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Oral and Injectable Medications for Type 2 Diabetes Market Size by Type
  2. 10.1.1 China Oral and Injectable Medications for Type 2 Diabetes Revenue by Type (2021-2032)
  3. 10.1.2 China Oral and Injectable Medications for Type 2 Diabetes Sales by Type (2021-2032)
  4. 10.1.3 China Oral and Injectable Medications for Type 2 Diabetes Price by Type (2021-2032)
  5. 10.2 China Oral and Injectable Medications for Type 2 Diabetes Market Size by Application
  6. 10.2.1 China Oral and Injectable Medications for Type 2 Diabetes Revenue by Application (2021-2032)
  7. 10.2.2 China Oral and Injectable Medications for Type 2 Diabetes Sales by Application (2021-2032)
  8. 10.2.3 China Oral and Injectable Medications for Type 2 Diabetes Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Oral and Injectable Medications for Type 2 Diabetes Market Size by Type
  2. 11.1.1 Asia Oral and Injectable Medications for Type 2 Diabetes Revenue by Type (2021-2032)
  3. 11.1.2 Asia Oral and Injectable Medications for Type 2 Diabetes Sales by Type (2021-2032)
  4. 11.1.3 Asia Oral and Injectable Medications for Type 2 Diabetes Price by Type (2021-2032)
  5. 11.2 Asia Oral and Injectable Medications for Type 2 Diabetes Market Size by Application
  6. 11.2.1 Asia Oral and Injectable Medications for Type 2 Diabetes Revenue by Application (2021-2032)
  7. 11.2.2 Asia Oral and Injectable Medications for Type 2 Diabetes Sales by Application (2021-2032)
  8. 11.2.3 Asia Oral and Injectable Medications for Type 2 Diabetes Price by Application (2021-2032)
  9. 11.3 Asia Oral and Injectable Medications for Type 2 Diabetes Market Size by Country
  10. 11.3.1 Asia Oral and Injectable Medications for Type 2 Diabetes Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Oral and Injectable Medications for Type 2 Diabetes Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Oral and Injectable Medications for Type 2 Diabetes Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Oral and Injectable Medications for Type 2 Diabetes Market Size by Type
  2. 12.1.1 SAMEA Oral and Injectable Medications for Type 2 Diabetes Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Oral and Injectable Medications for Type 2 Diabetes Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Oral and Injectable Medications for Type 2 Diabetes Price by Type (2021-2032)
  5. 12.2 SAMEA Oral and Injectable Medications for Type 2 Diabetes Market Size by Application
  6. 12.2.1 SAMEA Oral and Injectable Medications for Type 2 Diabetes Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Oral and Injectable Medications for Type 2 Diabetes Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Oral and Injectable Medications for Type 2 Diabetes Price by Application (2021-2032)
  9. 12.3 SAMEA Oral and Injectable Medications for Type 2 Diabetes Market Size by Country
  10. 12.3.1 SAMEA Oral and Injectable Medications for Type 2 Diabetes Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Oral and Injectable Medications for Type 2 Diabetes Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Oral and Injectable Medications for Type 2 Diabetes Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Oral and Injectable Medications for Type 2 Diabetes Value Chain Analysis
  2. 13.1.1 Oral and Injectable Medications for Type 2 Diabetes Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Oral and Injectable Medications for Type 2 Diabetes Production Mode & Process
  6. 13.2 Oral and Injectable Medications for Type 2 Diabetes Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Oral and Injectable Medications for Type 2 Diabetes Distributors
  9. 13.2.3 Oral and Injectable Medications for Type 2 Diabetes Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst